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OBJECTIVE—We have previously shown that serum insulin
levels decrease threefold and blood glucose levels remain normal
in mice fed a leucine-deﬁcient diet, suggesting increased insulin
sensitivity. The goal of the current study is to investigate this
possibility and elucidate the underlying cellular mechanisms.
RESEARCH DESIGN AND METHODS—Changes in metabolic
parameters and expression of genes and proteins involved in
regulation of insulin sensitivity were analyzed in mice, human
HepG2 cells, and mouse primary hepatocytes under leucine
deprivation.
RESULTS—We show that leucine deprivation improves hepatic
insulin sensitivity by sequentially activating general control non-
derepressible (GCN)2 and decreasing mammalian target of
rapamycin/S6K1 signaling. In addition, we show that activation
of AMP-activated protein kinase also contributes to leucine
deprivation–increased hepatic insulin sensitivity. Finally, we
show that leucine deprivation improves insulin sensitivity under
insulin-resistant conditions.
CONCLUSIONS—This study describes mechanisms underlying
increased hepatic insulin sensitivity under leucine deprivation.
Furthermore, we demonstrate a novel function for GCN2 in the
regulation of insulin sensitivity. These observations provide
a rationale for short-term dietary restriction of leucine for the
treatment of insulin resistance and associated metabolic dis-
eases. Diabetes 60:746–756, 2011
I
nsulin resistance is a common feature of many
metabolic diseases, including type 2 diabetes and
nonalcoholic fatty liver diseases. The hallmark of
insulin resistance is reduced glucose uptake in
muscle and adipose tissue, and increased glucose pro-
duction in liver (1,2). Various strategies have been proposed
to treat insulin resistance, including lifestyle modiﬁcations
and pharmacologic interventions (3,4).
Recently, there has been a growing interest in treating
insulin resistance with dietary manipulation of micronu-
trients, including branched-chain amino acids (BCAAs).
The BCAAs comprise the three essential amino acids
having nonlinear aliphatic side chains: leucine, isoleucine,
and valine. These amino acids not only serve as precursors
in protein synthesis but also play regulatory roles in in-
tracellular signaling (5).
Several studies have shown that dietary supplementa-
tion of leucine inﬂuences insulin sensitivity. For example,
Zhang and colleagues (6) recently demonstrated that in-
creased oral intake of leucine improves whole-body glu-
cose metabolism in mice maintained on a high-fat diet
(HFD). The effect of increasing dietary leucine, however,
is controversial. For example, other studies reported that
increased serum levels of leucine have no effect (7) or
increase insulin resistance in humans and in animal
models of obesity (8,9).
By contrast, our research has focused on the effect of
eliminating leucine from the diet. As shown in our previous
study (10), serum insulin levels decrease threefold in mice
fed a leucine-deﬁcient [(2) leu] diet. Blood glucose levels
remain normal in these mice, however, suggesting in-
creased insulin sensitivity. The goal of our current study is
to investigate this possibility and elucidate the underlying
molecular and cellular mechanisms.
In our current study, we observed that leucine depriva-
tion increases whole-body insulin sensitivity and insulin
signaling in liver. Furthermore, we show that leucine dep-
rivation improves hepatic insulin sensitivity by sequentially
activating general control nonderepressible (GCN)2 and de-
creasing mammalian target of rapamycin (mTOR) signaling.
In addition, we show that activation of AMP-activated pro-
tein kinase (AMPK) also contributes to increased hepatic
insulin sensitivity under leucine deprivation. Finally, we
show that leucine deprivation improves insulin sensitivity
under insulin-resistant conditions.
RESEARCH DESIGN AND METHODS
Chemicals and plasmids. Insulin and rapamycin were from Sigma and Tauto
Biotech (Shanghai, China), respectively. The vector p-CAGGS-DN-AMPK-IRES-
EGFP encoding dominant-negative AMPK protein was a gift from Dr. Jia Li,
Shanghai Institute of Materia Medica, China. The HA-tagged constitutively
active S6K1 expression plasmid was the Addgene plasmid 8991, originally
from John Blenis’s laboratory. Effectene Transfection Reagent was from
Qiagen (Hilden, Germany).
Animals and treatment. Male C57BL/6J mice were obtained from Shanghai
Laboratory Animal Co., Ltd. (Shanghai, China). GCN2 knockout (Gcn2
2/2)a n d
leptin receptor–deﬁcient (db/db) mice were provided by Dr. Douglas Cavener,
Penn State University, and Dr. Xiang Gao, Nanjing University, China, re-
spectively. Eight- to ten-week-old mice were maintained on a 12-h light/dark
cycle at 25°C. Control (nutritionally complete amino acid) and (2) leu diets
were obtained from Research Diets, Inc. (New Brunswick, NJ). All diets were
isocaloric and compositionally the same in terms of carbohydrate and lipid
component. At the start of the feeding experiments, mice were acclimated to
a control diet for 7 days and then randomly divided into control and (2)l e u
diet groups, with free access to control and (2) leu diets, respectively, for 7
days. In addition, a pair-fed group was included to distinguish the possible
inﬂuence of the minor reduction in food intake, as previously observed in
the (2) leu group (11). A subset of mice underwent glucose tolerance tests
(GTTs) and insulin tolerance tests (ITTs) before they were killed by CO2
inhalation. These experiments were conducted in accordance with the
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Cell culture and treatments. HepG2 cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) with 25 mmol/L glucose (Gibco, Invitrogen,
Carlsbad, CA), 10% FBS, 50 mg/mL penicillin and streptomycin at 37°C, and 5%
CO2–95% air. Control and (2) leu medium were prepared from amino acid-free
DMEM (Invitrogen) by adding back all the amino acids contained in regular
DMEM and without leucine only, respectively. For the rapamycin treatment,
cells were incubated with 50 nmol/L rapamycin for 1 h. To induce insulin
resistance, HepG2 cells were incubated with 18 mmol/L glucosamine for 18 h
in serum-free medium as previously described (12), followed by incubation in
serum-free (2) leu or control medium for 24 h in the presence of glucosamine.
The GCN2-knockdown (KO) stable cell lines were obtained by transfecting
pSilencer4.1-CMV-puro-GCN2 small interfering (si)RNA vector into HepG2
cells and selecting for stable clones in the presence of 0.5 mg/mL puromycin.
Isolation of primary hepatocytes. Male C57BL/6J mice were anesthetized by
intraperitoneal injection with chloral hydrate. Hepatocytes were prepared by
collagenase perfusion as described previously (13). Isolated hepatocytes were
resuspended in 10% FBS DMEM and incubated for 1 day before switching to
(2) leu medium.
Generation and administration of recombinant adenoviruses. The recom-
binant adenoviruses used for the S6K1 expression were generated using AdEasy
Vector System (Qbiogene, Montreal, Canada). Brieﬂy, S6K1 gene was cloned
into a transfer vector. The resulting plasmid was then linearized with PmeI
and cotransformed into Escherichia coli strain BJ5183 together with pAdEasy-1.
A f t e rt r a n s f o r m a t i o ni nD H 5 a for greater yields of DNA production, the
recombinant adenoviral construct was cleaved with PacI and transfected
into QBI-293A cells to produce viral particles. Adenoviruses were puriﬁed by
ultracentrifugation in cesium chloride gradient and quantiﬁed. Viruses were di-
luted in PBS and administered via tail vein injection, using 5 3 10
8 pfu/mice.
Blood glucose, serum insulin, GTT, ITT, and homeostasis model
assessment–insulin resistance index. Blood glucose levels were mea-
sured using a Glucometer Elite monitor. Serum insulin levels were measured
using the Mercodia Ultrasensitive Rat Insulin ELISA kit (ALPCO Diagnostic,
Salem, NH). GTTs and ITTs were performed by i.p. injection of 2 g/kg glucose
after overnight fasting and 0.75 units/kg insulin after 4-h fasting, respectively.
Homeostasis model assessment–insulin resistance (HOMA-IR) index was
calculated according to the formula: [fasting glucose levels (mmol/L)] 3
[fasting serum insulin (mU/mL)]/22.5.
Glycogen synthesis assay. HepG2 cells were incubated in (2) leu medium
for the indicated times before adding 100 nmol/L insulin and 1 mCi/mL [
3H]
glucose. Cells were incubated with control or (2) leu medium for 3 h before
harvesting for glycogen synthesis assays, as previously described (12).
In vivo insulin signaling assay. Mice maintained on different diets were
fasted for 6 h before insulin injection as previously described (13). Sections of
liver, soleus muscle, and abdominal fat were excised from anesthetized mice
and snap-frozen, as untreated controls. Three to ﬁve minutes after injection
with 2 units/kg of insulin via the portal vein, pieces of tissue section were
excised and snap-frozen for Western blot analysis.
Western blot analysis. Whole-cell lysates were isolated using RIPA lysis
buffer (150 mmol/L Tris-HCl, 50 mmol/L NaCl, 1% NP-40, 0.1% Tween 20).
Protease and phosphatase inhibitors were added to all buffers before
experiments.Westernblotanalysiswasperformedaspreviouslydescribed(11).
Protein concentrations were assayed using the BCA Kit (Pierce, Rockford, IL).
Primary antibodies (anti–p-insulin receptor, anti-insulin receptor, anti–p-AKT,
anti-AKT, anti–p-IRS1, anti-IRS1, anti–p-mTOR, anti-mTOR, anti–p-p70 S6K1,
anti-p70 S6K1, anti–p-S6, anti-S6, anti–p-GCN2, anti-GCN2, anti–p-ACC, anti-
ACC, anti–p-AMPK, anti–t-AMPK [all from Cell Signaling Technology, Danvers,
MA]), anti–p-IRS1, and HA probe (Y-11) were incubated overnight at 4°C, and
speciﬁc proteins were visualized by ECL Plus (Amersham Biosciences, Uppsala,
Sweden). Band intensities were measured using Quantity One (Bio-Rad Labo-
ratories, Hercules, CA) and normalized to total protein or actin.
Statistics. All data are expressed as means 6 SEM. Signiﬁcant differences
were assessed by two-tailed Student t test or one-way ANOVA followed by the
Student-Newman-Keuls test. P , 0.05 was considered statistically signiﬁcant.
RESULTS
Leucine deprivation increases whole-body insulin
sensitivity. Mice were fed a control, (2) leu, or pair-fed
diet for 7 days. As shown previously (14), leucine depri-
vation results in a decrease in leucine and increases in
isoleucine, valine, and several other amino acids in the
serum (Supplementary Fig. 1). Consistent with previous
observations (10), levels of serum insulin decreased,
but blood glucose levels remained unchanged, in leucine-
deprived mice in the fed state (data not shown). By contrast,
fasting blood glucose levels were lower in leucine-deprived
mice compared with control or pair-fed mice. Levels of
serum insulin were also decreased 50% in these mice (Fig.
1A). Consistent with these changes, the HOMA-IR index
was decreased in leucine-deprived mice (Fig. 1B). Glucose
tolerance and clearance were further examined by GTTs
and ITTs, respectively. Fifteen minutes after injection of
glucose, blood glucose levels were signiﬁcantly lower in
pair-fed and leucine-deprived mice compared with con-
trols, with lowest levels in leucine-deprived mice. In ad-
dition, blood glucose levels were decreased more quickly
after administration of insulin in leucine-deprived mice
compared with control or pair-fed mice (Fig. 1C).
Increased insulin sensitivity in mice under leucine dep-
rivation suggests an increase in insulin sensitivity in one
or more peripheral tissues, including liver, white adipose
tissue (WAT), and muscle. To test this possibility, we
examined the levels of phosphorylation of two key com-
ponents in the insulin signaling pathways (15), insulin re-
ceptor (IR) and protein kinase B (AKT), in these tissues
after infusion of insulin (2 units/kg) into the hepatic portal
vein, as described previously (13). As expected, insulin-
stimulated phosphorylation of IR and AKT was increased in
these tissues in leucine-deprived mice compared with mice
maintained on a control diet (Fig. 1D).
Leucine deprivation increases insulin sensitivity in
vitro. To determine whether leucine deprivation has a di-
rect effect on the insulin signaling in liver, we examined
the effect of leucine deprivation on insulin signaling in
both the human hepatoma–derived cell line HepG2 and
primary cultured mice hepatocytes. Consistent with our
in vivo observations (Fig. 1D), insulin-stimulated phos-
phorylation of IR and AKT was signiﬁcantly elevated
under leucine deprivation in HepG2 cells (Fig. 2A)a n d
primary cultured hepatocytes (Fig. 2B). Furthermore,
insulin-stimulated incorporation of glucose into glycogen
was signiﬁcantly increased in cells incubated in (2)l e u
medium for 36 h. Leucine deprivation, however, also in-
creased baseline levels of glucose incorporation into
glycogen (Fig. 2C).
Leucine deprivation increases insulin sensitivity by
decreasing mTOR/S6K1 signaling in vitro. Decreased
mTOR/S6K1 signaling has been shown to increase insulin
sensitivity (16,17). Because mTOR activity is decreased in
the livers of mice maintained on a (2) leu diet (14), we
speculated that mTOR/S6K1 signaling may regulate insulin
sensitivity under leucine deprivation.
To investigate this possibility, we examined levels of
phosphorylation of mTOR and its downstream targets, in-
cluding S6K1 and ribosomal protein S6, in HepG2 cells
incubated in (2) leu medium for 24 h. Levels of phos-
phorylation of these proteins were also used as indicators
for the activation status of mTOR (18). Consistent with
previous results (19), phosphorylation of these proteins
was decreased by leucine deprivation in HepG2 cells (Fig.
3A). Similar to the effect of leucine deprivation, pre-
treatment with the mTOR inhibitor 50 nmol/L rapamycin
for 1 h signiﬁcantly decreased phosphorylation of S6 in
HepG2 cells compared with pretreatment with vehicle. By
contrast, insulin-stimulated phosphorylation of IR and AKT
was increased signiﬁcantly in these cells (Fig. 3B).
If decreased mTOR/S6K1 signaling regulates hepatic
insulin sensitivity under leucine deprivation, upregulation
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rivation on enhancing insulin sensitivity. As predicted,
overexpression of CA-S6K1 (as conﬁrmed by Western
blotting using anti–HA-tagged antibody) increased S6
phosphorylation, but impaired phosphorylation of IR
and AKT, in HepG2 cells compared with control cells
(Fig. 3C). Consistent with these changes, phosphorylation of
IRS1 Ser636/639, a residue that has been shown to be regu-
lated by S6K1 (16,20), was increased in cells overexpress-
ing CA-S6K1 (Fig. 3C). Furthermore, insulin-stimulated
FIG. 1. Leucine deprivation improves insulin sensitivity in vivo. A–D: Mice were fed a control (ctrl), (2) leu, or pair-fed (pf) diet for 7 days,
followed by fasting overnight or indicated times before measuring blood glucose and serum insulin levels (A), calculating HOMA-IR index (B), and
carrying out GTT and ITT (C). Insulin signaling in liver, WAT, and muscle was examined before (2 Ins) and after (+ Ins) 2 units/kg insulin
stimulation for 3 to 5 min (D). Data are means 6 SEM of at least two independent experiments with mice of each group for each experiment (n=5–
6 each group). Statistical signiﬁcance is calculated by one-way ANOVA followed by the Student-Newman-Keuls test for the effects of either group
vs. control diet (*P < 0.01) and (2) leu vs. pair-fed diet (#P < 0.01) (A–C), or by two-tailed Student t test for the effects of (2) leu vs. control diet
after insulin stimulation (*P < 0.05) (D). Blood glucose and serum insulin levels (A), HOMA-IR index (B), GTT and ITT (C), and p-IR and p-AKT
protein (D)( top, Western blot; bottom, quantitative measurements of p-IR and p-AKT protein relative to their total protein).
LEUCINE DEPRIVATION AND INSULIN SENSITIVITY
748 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.orgincorporation of glucose into glycogen was also signiﬁ-
cantly decreased in these cells (Fig. 3D).
Leucine deprivation increases insulin sensitivity by
decreasing mTOR/S6K1 signaling in vivo. Consistent
with changes in vitro, phosphorylation of mTOR, S6K1, and
S6 was also decreased signiﬁcantly in the livers of leucine-
deprived mice compared with mice fed a control diet (Fig.
4A). By contrast, no differences in the levels of phosphory-
lation of these proteins were observed in the livers of pair-fed
mice compared with control diet–fed mice (data not shown).
FIG. 2. Leucine deprivation improves insulin sensitivity in vitro. A and B: Cells were incubated in control (+ leu) or leucine-deﬁcient (2 leu) medium
for indicated times, followed with (+ Ins) or without (2 Ins) 100 nmol/L insulin stimulation for 20 min. Data represent results from at least three
independent experiments. C: HepG2 cells were incubated in control or leucine-deﬁcient medium for 36 h, followed by a glycogen synthesis assay. Data
are means 6 SEM of at least three independent experiments. Statistical signiﬁcance is calculated by one-way ANOVA followed by Student-Newman-
Keuls test for the effects of any group vs. control medium without insulin stimulation (*P < 0.01), with vs. without insulin stimulation in (2)l e u
medium (#P < 0.01), or (2) leu vs. control medium after insulin stimulation (&P < 0.01). A and B: p-IR and p-AKT protein.C: Glycogen synthesis assay.
FIG. 3. Leucine deprivation increases insulin sensitivity by decreasing mTOR/S6K1 signaling in vitro. A: HepG2 cells were incubated in control (+
leu) or leucine-deﬁcient (2 leu) medium for 24 h. B: HepG2 cells were treated with (+ rapa) or without (2 rapa) 50 nmol/L rapamycin for 1 h,
followed with (+ Ins) or without (2 Ins) 100 nM insulin stimulation for 20 min. C and D: HepG2 cells were transfected with HA-tagged consti-
tutively active S6K1 (+ CA-S6K1) or control pRK7 vectors (2 CA-S6K1). Cells were incubated with (2) leu medium for 24 h followed by 100
nmol/L insulin stimulation for 20 min (C), or for 36 h followed by glycogen synthesis assay (D). Data are means 6 SEM of at least three in-
dependent experiments. Statistical signiﬁcance is calculated by two-tailed Student t test for the effects of (2) leu vs. control medium (*P < 0.01)
(A), with vs. without rapamycin after insulin stimulation (*P < 0.01) (B), with vs. without CA-S6K1 after insulin stimulation (*P < 0.01) (C), or by
one-way ANOVA followed by Student-Newman-Keuls test for the effects of any group vs. control medium without insulin stimulation (*P < 0.01),
and with vs. without insulin stimulation in (2) leu medium (#P < 0.01) (D). A: p-mTOR, p-S6K1, and p-S6 protein (left, Western blot; right,
quantitative measurements of p-mTOR, p-S6K1, and p-S6 protein relative to their total protein). B and C: p-IR, p-IRS1, p-AKT, p-S6 protein (left,
Western blot; right, quantitative measurements of p-IR, p-IRS1, p-AKT protein relative to their total protein). D: Glycogen synthesis assay.
F. XIAO AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 749To demonstrate the importance of S6K1 in increased
hepatic insulin sensitivity under leucine deprivation in
vivo, we investigated whether increased insulin sen-
sitivity can be blocked in leucine-deprived mice by
infecting mice with adenoviruses expressing CA-S6K1 (as
conﬁrmed by Western blotting using anti–HA-tagged an-
tibody). As predicted, these mice exhibited decreased
glucose clearance, compared with mice injected with ad-
enovirus that expresses green ﬂuorescent protein (Fig.
4B). Consistent with decreased whole-body insulin sen-
sitivity, insulin-stimulated phosphorylation of IR and AKT
was also greatly impaired in the livers of these mice (Fig.
4C).
Leucine deprivation increases insulin sensitivity by
activation of GCN2. GCN2 is a serine protein kinase that
is well known to function as a sensor for amino acid
deprivation (21–23). To examine the possible involve-
ment of GCN2 in the regulation of insulin sensitivity un-
der leucine deprivation, levels of GCN2 phosphorylation
in HepG2 cells incubated in (2) leu medium were ex-
amined. Consistent with previous results in mouse embry-
onic ﬁbroblasts (24), GCN2 phosphorylation was increased
in these cells (Fig. 5A). Furthermore, knocking down
expression of GCN2 in HepG2 cells (a stable cell line
transfected with siRNA GCN2 as examined by decreased
levels of GCN2 protein) signiﬁcantly decreased insulin-
stimulated phosphorylation of IR and AKT under leucine
deprivation (Fig. 5B).
Consistent with our in vitro results, levels of GCN2
phosphorylation were also increased in the livers of mice
maintained on a (2) leu diet for 7 days (Fig. 5C). The role
of GCN2 in the regulation of increased insulin sensitivity
under leucine deprivation was further examined in ITT
experiments using Gcn2
+/+ and Gcn2
2/2 mice. We found
that glucose clearance was decreased in Gcn2
2/2 mice,
compared with Gcn2
+/+ mice, fed a (2) leu diet (Fig. 5D).
Although fasting glucose levels in both strains of mice
were not different, fasting serum insulin levels were higher
in leucine-deprived Gcn2
2/2 mice (Fig. 5E). Consistent
with these changes, insulin-stimulated phosphorylation of
IR and AKT was decreased in the livers of Gcn2
2/2 mice
(Fig. 5F).
GCN2 functions as an upstream inhibitor of mTOR
under leucine deprivation. As shown previously (14), we
found that mTOR activity was not reduced by leucine
deprivation in the livers of Gcn2
2/2 mice (Fig. 6A), sug-
gesting that GCN2 may function as an upstream regulator
of mTOR. Consistent with this possibility, decreased
phosphorylation of mTOR and S6K1 by leucine depriva-
tion was not observed in GCN2-KO HepG2 cells (Fig. 6B).
If unrepressed mTOR/S6K1 activity was the cause of
decreased insulin signaling in GCN2-KO HepG2 cells in
FIG. 4. Leucine deprivation increases insulin sensitivity by decreasing mTOR/S6K1 signaling in vivo. A: Mice were fed a control (ctrl) or (2)l e u
diet for 7 days. B and C: Mice were infected with adenovirus HA-tagged constitutively active S6K1 (+ Ad-CA-S6K1) or control green ﬂuorescent
protein adenovirus (2 Ad-CA-S6K1) via tail-vein injection. ITT was examined after mice were fed a (2) leu diet at day 6 (B), and insulin signaling
was examined before (2 Ins) and after (+ Ins) 2 units/kg insulin stimulation for 3 min at day 7 (C). Data are means 6 SEM of at least two in-
dependent experiments with mice of each group for each experiment (n=5–7 each group). Statistical signiﬁcance is calculated by two-tailed
Student t test for the effects of (2) leu vs. control diet (*P < 0.05) (A) and with vs. without CA-S6K1 after insulin stimulation (*P < 0.01)
(B and C). p-mTOR, p-S6K1, and p-S6 protein (A)( left, Western blot; right, quantitative measurements of p-mTOR, p-S6K1, and p-S6 protein
relative to their total protein); ITT (B); p-IR, p-AKT, p-S6 protein (C)( left, Western blot; right, quantitative measurements of p-IR and p-AKT,
protein relative to their total protein).
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hibitor rapamycin should reverse these effects. As pre-
dicted, treatment with 50 nmol/L rapamycin increased
insulin-stimulated phosphorylation of IR and AKT in these
cells (Fig. 6C).
Leucine deprivation increases insulin sensitivity
via activation of AMPK. It has been shown pre-
viously that AMPK regulates insulin sensitivity and that
activation of AMPK is indirectly controlled by nutrient
availability (25,26). To determine a role of AMPK in
regulating insulin sensitivity under leucine deprivation,
we ﬁrst examined the levels of AMPK phosphorylation in
the livers of mice and in HepG2 cells under leucine
deprivation. As predicted, AMPK phosphorylation was
increased in the livers of mice fed a (2) leu diet for 7
days, compared with mice fed a control diet, and in
HepG2 cells incubated in (2) leu medium for 24 h (Fig.
7A).
To gain further insight into the signiﬁcance of AMPK
activation in regulating insulin sensitivity under leucine
deprivation, we examined whether downregulation of
AMPK reduces the effects of leucine deprivation on
insulin sensitivity. HepG2 cells were transfected with
a plasmid encoding a dominant-negative form of AMPKa1
(DN-AMPK), the effects of which were conﬁrmed by de-
creased phosphorylation of acetyl-CoA carboxylase, before
incubation with (2) leu medium for 24 h. As predicted,
overexpression of DN-AMPK decreased insulin-stimulated
phosphorylation of IR and AKT compared with control cells
(Fig. 7B). Levels of phosphorylation of IRS1 at Tyr612,
a residue that has been shown to be regulated by AMPK
(27), were also decreased in these cells.
Leucine deprivation increases insulin sensitivity under
insulin-resistant conditions in vivo and in vitro. To in-
vestigate whether leucine deprivation could also increase
insulin sensitivity in insulin-resistant conditions, we exam-
ined the effect of leucine deprivation on insulin sensitivity in
HepG2 cells, in which insulin resistance was induced by
pretreatment with 18 mmol/L glucosamine for 18 h (28).
The impaired insulin signaling was partially reversed by
incubating cells in (2) leu medium for 24 h (Fig. 8A).
Similar results were obtained in primary cultured hepatocytes
FIG. 5. Leucine deprivation increases insulin sensitivity by activation of GCN2. A: HepG2 cells were incubated with control (+ leu) or (2)l e u
medium for 24 h. B: The GCN2-KO stable HepG2 (+ GCN2 RNAi) and negative control cells (2 GCN2 RNAi) were incubated with (2) leu medium
for 24 h and followed with (+ Ins) or without (2 Ins) 100 nmol/L insulin stimulation for 20 min. Data are means 6 SEM of at least three in-
dependent experiments (A and B). C: Gcn2
+/+ mice were fed a control (ctrl) or (2) leu diet for 7 days. D–F: Gcn2
+/+ and Gcn2
2/2 mice were fed
a( 2) leu diet for 7 days, followed by ITT (D), overnight fasting blood glucose and serum insulin measurement (E), and insulin signaling exam-
ination before (2 Ins) and after (+ Ins) 2 units/kg insulin stimulation for 3 min (F). Data are means 6 SEM of at least two independent
experiments with mice of each group for each experiment (n=5–6 each group). Statistical signiﬁcance is calculated by two-tailed Student t test for
the effects of (2) leu vs. control medium (*P < 0.01) (A), GCN2-KO vs. control cells after insulin stimulation (B), (2) leu vs. control diet (C), and
Gcn2
2/2 vs. Gcn2
+/+ mice (D and E). p-GCN2 protein (A)( top, Western blot; bottom, p-GCN2 protein relative to total protein); p-IR and p-AKT
protein (B)( left, Western blot; right, quantitative measurements of p-IR and p-AKT protein relative to their total protein); p-GCN2 protein (C)
(top, Western blot; bottom, p-GCN2 protein relative to total protein); ITT (D); fasting blood glucose and serum insulin (E); p-IR and p-AKT
protein (F)( top, Western blot; bottom, quantitative measurements of p-IR and p-AKT protein relative to their total protein).
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16 weeks (Fig. 8B).
We next investigated whether leucine deprivation can
increase insulin sensitivity under insulin-resistant con-
ditions in vivo. Animal models of insulin resistance are
divided into two categories: nutritionally induced models,
such as that induced by HFD feeding (29), and geneti-
cally induced models, such as leptin receptor–deﬁcient
(db/db) mice (30). After maintenance on an HFD for 16
weeks, mice exhibited impaired glucose clearance, as
demonstrated in ITT assays (Fig. 8C). Decreased glu-
cose clearance in these mice, however, improved sig-
niﬁcantly after maintenance on a (2)l e uH F Df o r7d a y s
(Fig. 8C). Similar results were obtained in db/db mice
(Fig. 8D).
DISCUSSION
We have previously shown that leucine deprivation sig-
niﬁcantly decreases serum insulin levels without affecting
blood glucose levels in mice in the fed state (10), sug-
gesting increased insulin sensitivity. This possibility was
conﬁrmed in our current study by the decreased HOMA-IR
index and increased glucose clearance and tolerance in
leucine-deprived mice. Lower baseline levels of blood
glucose, however, could also account for the lower peak
as shown in the GTT and ITT results in these mice. As
previously reported, mice maintained on a (2)l e ud i e t
reduced their food intake by 15% (11). By using pair-fed
mice as a control, we demonstrated that this increased
insulin sensitivity is caused primarily by deﬁciency of
leucine, rather than the small reduction in food intake.
Consistent with previous reports (14), our study found
that leucine deprivation results in a decrease in leucine
and increases in isoleucine and valine in the serum. The
increased levels of serum isoleucine and valine, how-
ever, are unlikely to account for the increased insulin
sensitivity under leucine deprivation because the levels
of all three BCAAs and other amino acids are elevated
in insulin-resistant conditions in vivo (8,9) and in vitro
(31). Taken together, these results strongly suggest that
low levels of leucine are the critical factor correlating
with the increased insulin sensitivity in leucine-deprived
mice.
Insulin is secreted by pancreatic b-cells in response to
feeding and other stimuli and functions to regulate blood
glucose levels. Binding of insulin to its receptor leads to
tyrosine phosphorylation of IRS (15), which results in the
recruitment of the regulatory subunit of phosphoinositide
3-kinase (PI3K) to IRS. Activated PI3K phosphorylates and
activates 3-phosphoinositide–dependent protein kinase 1,
which stimulates AKT activation. Activated AKT in turn
activates glycogen synthase, stimulating the synthesis of
glycogen in the liver (15) or glucose uptake in the adipose
FIG. 6. GCN2 functions as an upstream inhibitor of mTOR under leucine deprivation. A: Gcn2
2/2 mice were fed a control (ctrl) or (2) leu diet for 7
days. B: GCN2-KO stable HepG2 (+ GCN2 RNAi) and negative control cells (2 GCN2 RNAi) were incubated with control (+ leu) or leucine-de-
ﬁcient (2 leu) medium for 24 h. C: GCN2-KO stable HepG2 cells were incubated in (2) leu medium for 24 h, then treated with (+ rapa) or without
(2 rapa) 50 nmol/L rapamycin for 1 h, followed with (+ Ins) or without (2 Ins) 100 nM insulin stimulation for 20 min. Data are means 6 SEM of at
least two independent experiments with mice of each group for each experiment (n=5–7 each group) (A) and at least three independent
experiments (B and C). Statistical signiﬁcance is calculated by two-tailed Student t test for the effects of (2) leu vs. control diet (A), one-way
ANOVA followed by Student-Newman-Keuls test for the effects of any group vs. control medium in control cells (*P < 0.01) (B), and with vs.
without rapamycin after insulin stimulation (*P < 0.01) (C). p-mTOR and p-S6K1 protein (A and B)( top, Western blot; bottom, quantitative
measurements of p-mTOR and p-S6K1 protein relative to their total protein); p-IR, p-AKT, and p-S6 protein (C)( top, Western blot; bottom,
quantitative measurements of p-IR and p-AKT protein relative to their total protein).
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leucine deprivation increases insulin signaling in all the
tissues examined, including liver, WAT, and muscle, con-
sistent with increased insulin sensitivity.
mTOR is a serine-threonine protein kinase that has been
shown to be essential for protein synthesis, growth,
development, and proliferation (18,33,34). Studies have
shown that mTOR activity is regulated by BCAA availability,
especially leucine (35). For example, mTOR activity is in-
creased by elevated extracellular levels of leucine (33). By
contrast, its activity is decreased in the livers of mice under
leucine deprivation (14). Activation of mTOR/S6K1 sig-
naling has been shown to contribute to the development
of insulin resistance. Recent studies demonstrate that
the mTOR downstream target S6K1 directly phosphor-
ylates IRS1 serine residues, including Ser-302/307 (36),
Ser-307/312 (37), Ser-632/636 (20), and Ser-1097/1101
(38). Increased IRS1 serine phosphorylation reduces the
activity of IRS1, thereby impairing PI3K/AKT signaling and
increasing insulin resistance (39,40). This effect is reversed
in vitro by rapamycin (37). Consistent with these results,
mice deleted for S6K1 have reduced phosphorylation of
IRS1 Ser-636 (16) and do not develop diet-induced insulin
resistance.
On the basis of these studies, we hypothesized that
leucine deprivation increases insulin sensitivity by de-
creasing mTOR/S6K1 activity. Consistent with our hy-
pothesis, decreased mTOR/S6K1 signaling in the livers of
mice and HepG2 cells under leucine deprivation was ob-
served. Furthermore, overexpression of CA-S6K1 inhibited
insulin signaling in HepG2 cells incubated in (2)l e u
medium. A key role for S6K1 in the regulation of insulin
sensitivity was conﬁrmed in mice injected with adeno-
viruses expressing CA-S6K1. These mice exhibited de-
creased glucose clearance and insulin signaling in liver,
compared with control mice, when fed a (2) leu diet. Taken
together, our ﬁndings demonstrate an important role for
mTOR/S6K1 in the regulation of insulin sensitivity under
leucine deprivation.
To look for upstream regulators for mTOR, our atten-
tion was drawn to the amino acid sensor GCN2, a kinase
that is activated by uncharged tRNAs in response to
deprivation of essential amino acids, including leucine, in
yeast and mammals (21–23). Activated GCN2 phosphor-
ylates eukaryotic initiation factor 2-a, thereby repressing
general protein synthesis, but increasing translation of
proteins related to amino acid biosynthesis and transport
(41–44). We recently demonstrated that GCN2 also reg-
ulates lipid metabolism during leucine deprivation (10).
Because deﬁciency in amino acid is sensed by GCN2,
we speculated that GCN2 may also regulate glucose uti-
lization by modulating insulin sensitivity during leucine
deprivation.
Consistent with this hypothesis, knocking down ex-
pression of GCN2 using siRNA decreased insulin signaling
in HepG2 cells incubated in (2) leu medium. The key role
for GCN2 in the regulation of insulin sensitivity was con-
ﬁrmed by the observation that Gcn2
2/2 mice exhibited
decreased glucose clearance, compared with wild-type
mice, when fed a (2) leu diet. Consistent with these results,
higher serum insulin levels were required to maintain the
same levels of fasting blood glucose in Gcn2
2/2 mice
compared with Gcn2
+/+ mice. In addition, we provide ev-
idence that GCN2 regulates insulin sensitivity via in-
hibition of mTOR activity during leucine deprivation. Thus,
in addition to regulation of amino acid and lipid metabo-
lism (10,14), GCN2 also functions in glucose metabolism.
Taken together, our results strongly suggest that GCN2
functions as a master regulator of metabolic adaptation to
deprivation of essential amino acids. The mechanism by
which leucine deprivation activates GCN2 requires further
investigation.
FIG. 7. Leucine deprivation improves insulin sensitivity via activation of AMPK. A: Mice were fed a control (ctrl) or (2) leu diet for 7 days, and
HepG2 cells were incubated with control (+ leu) or leucine-deﬁcient (2 leu) medium for 24 h. B: HepG2 cells were transfected with dominant-
negative form of AMPKa1 (+ DN-AMPK) or empty vectors (2 DN-AMPK). After incubation with (2) leu medium for 24 h, cells were stimulated
with (+ Ins) or without (2 Ins) 100 nmol/L insulin for 20 min. Data are means 6 SEM of at least three independent experiments. Statistical
signiﬁcance is calculated by two-tailed Student t test for the effects of (2) leu vs. control treatment (*P < 0.01) (A) and with vs. without DN-
AMPK after insulin stimulation (B). p-AMPK protein (A)( top, Western blot; bottom, quantitative measurements of p-AMPK protein relative to
their total protein); p-IR, p-IRS1, p-AKT, p-ACC protein (B)( left, Western blot; right, quantitative measurements of p-IR, p-IRS1, and p-AKT
proteins relative to their total protein).
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completely block the increased insulin signaling under
leucine deprivation suggests the possible involvement of
other regulatory pathways. Recent studies indicate that
AMPK also plays a role in the regulation of insulin sensi-
tivity by directly phosphorylating IRS1 (45) or by phos-
phorylating the mTOR upstream inhibitor TSC2 (46). AMPK
activators, including metformin and rosiglitazone, in-
crease insulin sensitivity and are used clinically in the
treatment of type 2 diabetes (2). These studies raise
the possibility that activation of AMPK may contribute
to the enhancement of insulin sensitivity under leucine
deprivation.
As predicted, leucine deprivation increased levels of
activated AMPK in vivo and in vitro. A key role for AMPK
in regulating insulin sensitivity under leucine deprivation
was conﬁrmed by the observed decreases in insulin sig-
naling in HepG2 cells transfected with DN-AMPK. The
mechanism by which leucine deprivation activates AMPK
is unknown. Furthermore, our current results did not dis-
tinguish whether AMPK directly regulates IRS1 phosphory-
lation or indirectly regulates insulin sensitivity by modulating
mTOR activity. These issues will be investigated in future
studies.
A previous study showed that mice deleted for the
BCATm gene encoding the enzyme catalyzing the ﬁrst
step in peripheral BCAA metabolism, which would also be
expected to have low leucine, valine, or isoleucine use,
exhibited increased sensitivity (47). These results suggest
that deﬁciency of other BCAAs may also have similar
effects on insulin sensitivity. Consistent with this hypoth-
esis, our study found that valine deprivation also increases
hepatic insulin sensitivity compared with those under
control or glycine (a nonessential amino acid)–deﬁciency
treatment (F.X., F.G., unpublished observations). Further-
more, the effects of valine deprivation on insulin sensitivity
are mediated by GCN2 activation (F.X., F.G., unpublished
observations). On the basis of these observations, we plan
to carry out a systematic analysis of the effects of deﬁciency
of isoleucine and other essential amino acids in the future.
The current study also found that leucine deprivation
increases insulin sensitivity under insulin-resistant con-
ditions, both in vitro and in vivo, suggesting potential ap-
plication of this diet in treating type 2 diabetes. Clinical use
FIG. 8. Leucine deprivation improves insulin sensitivity under insulin-resistant conditions. A: HepG2 cells were incubated with 18 mmol/L glu-
cosamine for 18 h before being incubated with control (+ leu) or leucine-deﬁcient (2 leu) medium for 24 h in the presence of glucosamine, followed
with (+ Ins) or without (2 Ins) 100 nM insulin stimulation for 20 min. B: Primary hepatocytes isolated from insulin-resistant mice, induced by HFD
feeding for 16 weeks, were incubated in control or leucine-deﬁcient medium for 24 h, followed by stimulation with 100 nmol/L insulin for 20 min.
Data represent results from at least three independent experiments (A and B). C: Mice were fed an HFD for 16 weeks and then an HFD or (2)l e u
HFD for 7 days, followed by ITT. Age-matched, chow-diet fed (ctrl) mice were also included. D: Leptin receptor–deﬁcient (db/db) were fed control
or (2) leu diet for 7 days, followed by ITT. Their control littermates (wild type) fed a control diet were also included. Data are means 6 SE of at
least two independent experiments with mice of each group for each experiment (n=5–7 each group) (C and D). Statistical signiﬁcance is cal-
culated by one-way ANOVA followed by Student-Neuman-Keuls test for the effects of either group vs. HFD (*P < 0.01) (C), either group vs. control
diet in db/db mice (*P < 0.01) (D), and (2) leu diet in db/db mice vs. control diet in wild-type mice (#P < 0.01) (D). p-IR and p-AKT protein (A and
B); ITT (C and D); working model (E). GlcN, glucosamine; WT, wild type.
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of short- and long-term leucine deprivation in humans has
not been examined. Determining the optimal concentra-
tion of leucine and the duration of therapeutic (2) leu
diets will be important in future studies.
In summary, we have shown that leucine deprivation
improves insulin sensitivity under normal and insulin-
resistant conditions, both in vitro and in vivo. Further-
more, the GCN2/mTOR/S6K1 and AMPK pathways play
important roles in the regulation of hepatic insulin sen-
sitivity by leucine deprivation. The relative contribution
of each of these pathways remains to be demonstrated. It
also remains to be demonstrated whether these pathways
function in the regulation of insulin sensitivity in other
tissues, including muscle and WAT.
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